Navigation Links
Percutaneous Tibial Nerve Stimulation Included in the American Urological Association's Overactive Bladder Clinical Treatment Guidelines
Date:5/21/2012

MINNEAPOLIS, May 21, 2012 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today announced that the American Urological Association (AUA) issued a clinical guideline titled "Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults," which includes percutaneous tibial nerve stimulation (PTNS) as an integral part of the care path for overactive bladder (OAB) treatment. The AUA's evidence-based guidelines are intended to promote the highest standards of clinical care. Uroplasty's Urgent® PC Neuromodulation System is the only FDA cleared device that delivers PTNS.

"It is noteworthy that the world's most prestigious urology society has recognized the clinical significance of PTNS in their OAB treatment guidelines," said David Kaysen, President and CEO of Uroplasty.  "We will present these guidelines to the medical directors of U.S. private payers and Medicare carriers as we continue our efforts to expand coverage for our Urgent PC Neuromodulation System."

About Uroplasty, Inc.

Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom, is a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions. Our focus is the continued commercialization of our Urgent PC system, which we believe is the only FDA-approved minimally invasive nerve stimulation device designed for office-based treatment of urinary urgency, urinary frequency and urge incontinence – symptoms often associated with overactive bladder.

We also offer Macroplastique Implants®, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. For more information on the company and its products, please visit Uroplasty, Inc. at www.uroplasty.com.

Forward-Looking Information

This press release contains forward-looking statements that reflect our best estimates regarding future events and financial performance. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our anticipated results. We discuss in detail the factors that may affect the achievement of our forward-looking statements in our Annual Report on Form 10-K filed with the SEC.  In particular, we cannot be certain that we will ever achieve sustained profitability, that the rate of reimbursement for PTNS treatments will be adequate to justify the cost of our product, that other Medicare carriers or private payers will provide coverage for this treatment or that existing carriers and payers will not change their coverage decisions, that the rate of adoption of our products by new customers will continue, or that any of the other risks identified in our 10-K will not adversely affect our expectations as described in these forward-looking statements.

For Further Information:

Uroplasty, Inc.

David Kaysen, President and CEO, or

Medi Jiwani, Vice President, CFO, and Treasurer,

952.426.6140

 

EVC Group

Jenifer Kirtland (Investors)

415.568.9349

Chris Gale (Media)

646.201.5431


'/>"/>
SOURCE Uroplasty, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Preclinical Study Examines Use of nContacts Technology in Enabling a Percutaneous Device Approach to Epicardial Ablation
2. Boston Scientific Receives FDA Approval for New Infinion™ 16 Percutaneous Lead for Precision Plus™ Spinal Cord Stimulator System
3. United Kingdoms National Institute for Health and Clinical Excellence Issues Guidance on Percutaneous Tibial Nerve Stimulation for Faecal Incontinence
4. PROTECT II Interim Results Demonstrate That Impella Is Not Superior to the Intra-Aortic Balloon Pump in Reducing Major Adverse Events in High Risk Patients Receiving Percutaneous Coronary Interventions
5. Interventional Spine®, Inc. Announces Continued Success With Its Unique PERPOS® Percutaneous Cervical System
6. OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months
7. Acne Scars Significantly Improved by a Combination Treatment of Photodynamic Therapy and Percutaneous Collagen Induction
8. First Swiss Patients Treated with the Percutaneous MitraClip(R) System
9. Portola Pharmaceuticals Initiates Phase II Trial of Novel IV and Oral Anti-Platelet Drug in Non-Urgent Percutaneous Coronary Intervention
10. First European Patients Treated With the Percutaneous MitraClip(R) System
11. Myocor Receives Approval for Percutaneous Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... YORK , March 24, 2017 ... and Equipment stocks, which are: Neovasc Inc. (NASDAQ: NVCN), Hologic ... Heart Inc. (NASDAQ: SSH ). These companies are ... its prior gains on Thursday, March 23 rd , 2017, ... afternoon, while shares of health care companies in the S&P ...
(Date:3/24/2017)... BOTHELL, Wash. , March 23, 2017 /PRNewswire/ ... developer of advanced medical technology for non-invasive surgery, ... the Mirabilis System for treatment of uterine fibroids ... that it had received approval from the US ... study of the Mirabilis System in the United ...
(Date:3/23/2017)... Mosaic Life Care, based in St. Joseph, Missouri , ... network of 58 clinics, located in 22 cities, and its flagship St. Joseph Medical ... improve the delivery of health care to its patients, including the insurance, billing and ... ... Mosaic Life Care St. Joseph Medical Center ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... March 24, 2017 , ... Gastro Health ... to prep patients for colonoscopy at the HyGIeaCare® Center that is to be ... FL. , The HyGIeaCare® Prep, cleared by the U.S. Food and ...
(Date:3/24/2017)... ... March 24, 2017 , ... “End Time GPS”: a ... will interrelate. “End Time GPS” is the creation of published author, Wesley Gerboth, ... working on military munitions and space-vehicle projects. Now, at age ninety-one, he shares the ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... In 2016 ... now estimates that there could be four million Zika-related cases in the Americas within ... with numbers of US cases reported per year skyrocketing to an estimated 329,000. Yet, ...
(Date:3/23/2017)... ... , ... Texas Physical Therapy Specialists (TexPTS) is pleased to announce the ... clinic is the group’s second in New Braunfels and 22nd in Texas. , TexPTS ... location brings things full circle for the group, “It’s crazy to think that we ...
(Date:3/23/2017)... ... 23, 2017 , ... 82% of adults are unaware of the dangers that infectious bacteria play ... the minimum two times a day that dentists recommend. The ramifications of improper oral upkeep ... school and adults missing 164 million hours of work each year due to dental issues. ...
Breaking Medicine News(10 mins):